2018 - 2019年结直肠癌手术及辅助治疗的重要进展
Essential advances in surgical and adjuvant therapies for colorectal cancer 2018-2019.
作者信息
Akagi Tomonori, Inomata Masafumi
机构信息
Department of Gastroenterological and Pediatric Surgery Faculty of Medicine Oita University Yufu-City Japan.
出版信息
Ann Gastroenterol Surg. 2020 Jan 28;4(1):39-46. doi: 10.1002/ags3.12307. eCollection 2020 Jan.
Abstract
Surgical resection and adjuvant chemotherapy are the only treatment modalities for localized colorectal cancer that can obtain a "cure." The goal in surgically treating primary colorectal cancer is complete tumor removal along with dissection of systematic D3 lymph nodes. Adjuvant treatment controls recurrence and improves the prognosis of patients after they undergo R0 resection. Various clinical studies have promoted the gradual spread and clinical use of new surgical approaches such as laparoscopic surgery, robotic surgery, and transanal total mesorectal excision (TaTME). Additionally, the significance of adjuvant chemotherapy has been established and it is now recommended in the JSCCR (the Japanese Society for Cancer of the Colon and Rectum) guideline as a standard treatment. Herein, we review and summarize current surgical treatment and adjuvant chemotherapy for localized colorectal cancer and discuss recent advances in personalized medicine related to adjuvant chemotherapy.
摘要
手术切除和辅助化疗是局限性结直肠癌唯一可实现“治愈”的治疗方式。手术治疗原发性结直肠癌的目标是完整切除肿瘤并清扫系统性D3淋巴结。辅助治疗可控制复发并改善患者接受R0切除后的预后。各种临床研究推动了诸如腹腔镜手术、机器人手术和经肛门全直肠系膜切除术（TaTME）等新手术方法的逐渐推广和临床应用。此外，辅助化疗的重要性已得到确立，目前在日本结直肠癌学会（JSCCR）指南中被推荐为标准治疗方法。在此，我们回顾并总结局限性结直肠癌的当前手术治疗和辅助化疗情况，并讨论辅助化疗相关个性化医疗的最新进展。
相似文献
1
Essential advances in surgical and adjuvant therapies for colorectal cancer 2018-2019.
Ann Gastroenterol Surg. 2020 Jan 28;4(1):39-46. doi: 10.1002/ags3.12307. eCollection 2020 Jan.
2
[Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer].
Zhonghua Wei Chang Wai Ke Za Zhi. 2022 Jun 25;25(6):522-530. doi: 10.3760/cma.j.cn441530-20210811-00321.
3
Changes in colorectal cancer care in japan before and after guideline publication: a nationwide survey about D3 lymph node dissection and adjuvant chemotherapy.
J Am Coll Surg. 2014 May;218(5):969-977.e1. doi: 10.1016/j.jamcollsurg.2013.12.046. Epub 2014 Feb 2.
4
Transanal total mesorectal excision (taTME) for rectal cancer: a training pathway.
Surg Endosc. 2016 Sep;30(9):4130-5. doi: 10.1007/s00464-015-4680-1. Epub 2015 Dec 10.
5
Surgical approach in locally advanced colorectal cancer--combined, extended and compound surgery.
Khirurgiia (Sofiia). 2013(4):29-50.
6
An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesorectal excision (TaTME).
Colorectal Dis. 2018 Sep;20 Suppl 6:33-46. doi: 10.1111/codi.14376.
7
Outcomes of open vs laparoscopic vs robotic vs transanal total mesorectal excision (TME) for rectal cancer: a network meta-analysis.
Tech Coloproctol. 2023 May;27(5):345-360. doi: 10.1007/s10151-022-02739-1. Epub 2022 Dec 12.
8
Robotic or transanal total mesorectal excision (TaTME) approach for rectal cancer, how about both? Feasibility and outcomes from a single institution.
J Robot Surg. 2022 Feb;16(1):149-157. doi: 10.1007/s11701-021-01206-7. Epub 2021 Mar 11.
9
Feasibility of transanal total mesorectal excision (taTME) using the Medrobotics Flex® System.
Surg Endosc. 2020 Jan;34(1):485-491. doi: 10.1007/s00464-019-07019-y. Epub 2019 Jul 26.
10
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.
Int J Clin Oncol. 2015 Apr;20(2):207-39. doi: 10.1007/s10147-015-0801-z. Epub 2015 Mar 18.
引用本文的文献
1
ALKBH5-mediated NPC2 mRNA mA demethylation promotes resistance to oxaliplatin in colorectal cancer.
Funct Integr Genomics. 2025 Jul 19;25(1):158. doi: 10.1007/s10142-025-01651-9.
2
Updated insights into the impact of adjuvant chemotherapy on recurrence and survival after curative resection of liver or lung metastases in colorectal cancer: a rapid review and meta-analysis.
World J Surg Oncol. 2025 Feb 18;23(1):56. doi: 10.1186/s12957-025-03714-4.
3
Development and validation of a dynamic nomogram for individualized prediction of survival in patients with colon cancer.
Sci Rep. 2024 Nov 14;14(1):28033. doi: 10.1038/s41598-024-78783-8.
4
The National Burden of Colorectal Cancer in the United States from 1990 to 2019.
Cancers (Basel). 2024 Jan 1;16(1):205. doi: 10.3390/cancers16010205.
5
Network pharmacology and bioinformatics were used to construct a prognostic model and immunoassay of core target genes in the combination of quercetin and kaempferol in the treatment of colorectal cancer.
J Cancer. 2023 Jul 3;14(11):1956-1980. doi: 10.7150/jca.85517. eCollection 2023.
6
Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients.
Front Oncol. 2023 Jan 16;13:1122669. doi: 10.3389/fonc.2023.1122669. eCollection 2023.
7
Quantitative evaluation of anastomotic perfusion during colorectal surgery via indocyanine green fluorescence angiography: a narrative review.
Ann Transl Med. 2022 Dec;10(24):1402. doi: 10.21037/atm-22-5312.
8
A comparative study of the pathological outcomes of robot-assisted versus open surgery for rectal cancer.
Ann Coloproctol. 2024 Apr;40(2):154-160. doi: 10.3393/ac.2022.00332.0047. Epub 2022 Dec 28.
9
Association of tumor size in pathological T4 colorectal cancer with desmoplastic reaction and prognosis.
Ann Gastroenterol Surg. 2022 Mar 21;6(5):667-678. doi: 10.1002/ags3.12571. eCollection 2022 Sep.
10
High postoperative carcinoembryonic antigen as an indicator of high-risk stage II colon cancer.
Oncol Lett. 2022 May;23(5):167. doi: 10.3892/ol.2022.13287. Epub 2022 Mar 30.
本文引用的文献
1
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
JAMA Oncol. 2019 Nov 1;5(11):1574-1581. doi: 10.1001/jamaoncol.2019.2572.
2
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.
Int J Clin Oncol. 2020 Jan;25(1):1-42. doi: 10.1007/s10147-019-01485-z. Epub 2019 Jun 15.
3
Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
J Clin Oncol. 2019 Jun 1;37(16):1436-1447. doi: 10.1200/JCO.19.00281. Epub 2019 Apr 15.
4
Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial.
Ann Surg. 2019 Apr;269(4):589-595. doi: 10.1097/SLA.0000000000003002.
5
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.
6
Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Lancet Gastroenterol Hepatol. 2018 Jan;3(1):47-56. doi: 10.1016/S2468-1253(17)30297-2. Epub 2017 Oct 24.
7
Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial.
JAMA. 2017 Oct 24;318(16):1569-1580. doi: 10.1001/jama.2017.7219.
8
Robotic Versus Laparoscopic Minimally Invasive Surgery for Rectal Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Ann Surg. 2018 Jun;267(6):1034-1046. doi: 10.1097/SLA.0000000000002523.
9
Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial.
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):261-268. doi: 10.1016/S2468-1253(16)30207-2. Epub 2017 Feb 2.
10
Pathologic Outcomes of Laparoscopic vs Open Mesorectal Excision for Rectal Cancer: A Systematic Review and Meta-analysis.
JAMA Surg. 2017 Apr 19;152(4):e165665. doi: 10.1001/jamasurg.2016.5665.
Zotero 插件